This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Breast cancer	Basic helix-loop-helix family member e41 (BHLHE41; BHLHB3; DEC2)	<p>Patient sample and mouse studies suggest BHLHE41 could help treat and diagnose triple-negative breast cancer. In primary triple-negative breast cancer samples, high <i>BHLHE41</i> expression was correlated with increased survival and reduced probability of metastasis. In mice injected with metastatic breast cancer cells, low <i>BHLHE41</i> expression led to metastasis to the lung, whereas <i>BHLHE41</i> overexpression did not. Next steps include identifying a compound that upregulates BHLHE41 and evaluating the prognostic value of <i>BHLHE41</i> expression in larger patient cohorts.</p> <p><i>SciBX</i> 5(29); doi:10.1038/scibx.2012.751 Published online July 26, 2012</p>	Diagnostic applications of <i>BHLHE41</i> in breast cancer patented; licensed to an undisclosed company for development of a diagnostic kit	<p>Montagner, M. <i>et al. Nature</i>; published online July 8, 2012; doi:10.1038/nature11207 Contact: Stefano Piccolo, University of Padua School of Medicine, Padua, Italy e-mail: piccolo@bio.unipd.it</p>